Factory High Quality Oritavancin CAS 171099-57-3

• Customization: Available
• CAS No.: 171099-57-3
• Formula: C86h97cl3n10o26
• Model NO.: 171099-57-3
• Classification: Specific Reagents
• Specific Usage: For Biological Purpose, For Microbiological, Pro Analysis
• Content: Standard
• Usage: Laboratory Reagents
• Source: Dry Powder
• Application: Scientific Research, Health
• Property: Organic Reagent
• Density: 1.59g/cm3
• Transport Package: as Demanded
• Specification: CP, USP, EP
• Trademark: Worldyang
• Origin: China
• HS Code: 3808929090
• Production Capacity: 1000kg/Year

Product Description

Shanghai Worldyang chemical Co., Ltd is a high-tech enterprise focused on industry of fine chemicals research and develop, produce and sale. Shanghai Worldyang chemical Co., Ltd is located in Shanghai China. we have the ability to provide you high quality products. More than 90 % of our products are exported to developed countries and regions such as north America, Europe, Japan, South Korea and the Middle East.

Products are widely used in pesticides, plastics, cosmetics, spices fragrance, water treatment, environmental protection, electronic chemicals and other fields. Up to now, we have established manufacturing bases in Anhui, jiangsu and guangdong separately, at the same time, we build closely cooperative relationship with the well-known universities and institutions of China to research new products constantly.

In addition, we also provide customized services for chemicals and organ silicon for customers around the world. Up the tonnage level down to the gram level can be provided to meet the different needs of our customers. We are good at a variety of reactions, including halogen exchange fluorination, halogenation, nitration, diazotization, grignard and reduction.
 

Oritavancin (Orbactiv)
CAS: 171099-57-3
Appearance: White powder
Certification: ISO 9001:2015; GMP
Specification: CP, USP, EP

Overview

Oritavancin, marketed under the brand name Orbactiv, is an innovative antibiotic approved by the FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It stands out as the first and only single-dose antibiotic treatment for ABSSSIs, where just one infusion completes the entire therapy. This approval marks a significant advancement in the treatment of bacterial skin infections, far exceeding current clinical standards.

Applications

Oritavancin injection (IV) is FDA-approved for adult patients with ABSSSIs caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). As a next-generation semi-synthetic glycopeptide antibiotic, following earlier glycopeptides such as vancomycin and teicoplanin, Oritavancin offers a durable antibacterial effect and is specifically designed to treat Gram-positive bacterial infections, including MRSA-related ABSSSIs.

Compared to other therapies, Oritavancin presents several advantages:

• Reduced cross-resistance, minimizing the risk of resistance development.
• A single-dose treatment regimen that simplifies therapy and improves patient compliance.

Research and Development

Our research team has successfully leveraged vancomycin-producing strains as the starting point to reconstruct the biosynthetic system for the precursor A82846B using synthetic biology techniques. This breakthrough has achieved a fermentation yield of over 1 gram per liter in shake flasks, marking a significant technological advancement in Oritavancin production.

Name	ORITAVANCIN
CAS Number	171099-57-3
Standard	CP, USP, EP
Package	1kg/drum, 25kg/drum and as demanded